Experiment 69155

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismRheum species (POLYGONACEAE)
CitationMANTANI,N: SEKIYA,N: SAKAI,S: KOGURE,T: SHIMADA,Y: TERASAWA,K:. (2002). RHUBARB USE IN PATIENTS TREATED WITH KAMPO MEDICINES- A RISK FOR GASTRIC CANCER?. 122(6)
Amount utilized
Compound isolated
DiseaseTHE PRESENT STUDY ASSESSED PATIENTS DIAGNOSED WITH GASTRIC CANCER DURING THE PERIOD BETWEEN 1979 AND 1999, WHO HAD BEEN ADMINISTERED RHUBARB BEFORE THE DEVELOPMENT OF GASTRIC CANCER. AMONG THE 10 ENROLLED PATIENTS, ONLY 2 PATIENTS HAD BEEN ADMINISTERED RHUBARB BEFORE THE DEVELOPMENT OF GASTRIC CARCINOMA. THE OTHER 8 PATIENTS HAD NEVER RECEIVED RHUBARB BEFORE THE DEVELOPMENT OF GASTRIC CARCINOMA. RHUBARB USE MAY HAVE LITTLE CONNECTION WITH THE DEVELOPMENT OF GASTRIC CANCER IN PRACTICE, EVEN IF SOME INGREDIENTS IN RHUBARB HAVE SHOWN CARCINOGENIC ACTIVITY IN EXPERIMENTAL STUDIES.
Number1
Qualitative resultINACTIVE
AnimalHUMAN ADULT
Dose expressionDOSE
ExtractTYPE EXT NOT STATED
GenderGIVEN TO BOTH SEXES